ArticleFrontiers in endocrinology2025
Multimodal ultrasound features for distinguishing classic and aggressive subtypes of papillary thyroid carcinoma.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Interpretable SVM-Based Integrated Ultrasound Model for Preoperative Thyroid Nodule Subtype Classification: Improved Identification of Follicular Variant Papillary Thyroid Carcinoma.Diagnostics (Basel, Switzerland) · 2026Article
- Predictive value of conventional ultrasonographic features combined with clinical factors for capsular invasion in papillary thyroid carcinoma with Hashimoto's thyroiditis.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To compare the sonographic features of papillary thyroid carcinoma (PTC) between classic and aggressive PTC subtypes to determine whether multimodal ultrasound (US) can aid in differentiating particular subtypes. Methods: The retrospective cohort study included patients with histologically proven PTCs according to the World Health Organization classification of thyroid neoplasms between December 2022 and October 2024. Imaging findings were evaluated using the International Expert Consensus on US Lexicon for Thyroid Nodules. Associations between US features and intrinsic subtypes were assessed by the χ Results: Overall, 295 patients with 320 nodules (74 males with 81 nodules and 221 females with 239 nodules) were included. There were 279 classic PTC (87.2%), 26 tall cell (8.1%), 11 hobnail (3.4%), one columnar cell (0.3%), one solid (0.3%), and two diffuse sclerosing subtypes (0.6%). Regarding US features, direction of growth, extrathyroidal extension (ETE), calcifications, and color Doppler flow imaging significantly differed among the PTC subtypes. Tall cell subtype PTCs exhibited the highest prevalence of taller-than-wide shapes ( Conclusion: There were significant differences and several trends in the US characteristics of different intrinsic subtypes, providing imaging diagnostic criteria to assist in managing individuals with PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.